Abstract The enhancer of Zeste homolog 2 (EZH2), a component of the Polycomb Repressive Complex 2 (PRC2), is an epigenetic silencer that is known to be highly expressed in both metastatic and primary prostate cancer (PCa). More recently, topoisomerase IIα (TOP2A), an enzyme that controls the topologic states of DNA during the cell cycle, has also been identified as being highly expressed in PCa. Both EZH2 and TOP2A have been associated with more aggressive disease and poorer prognostic outcome. During genome-wide analysis, using The Cancer Genome Atlas (TCGA), EZH2 and Top2A were found to be highly positively correlated, most noticeably in PCa and clear cell Renal Cell Carcinoma (ccRCC). As a result, we predicted increased expression of both EZH2 and TOP2A in an individual, would predict for a worse prognostic outcome than either gene being highly expressed alone. Further analysis of the TCGA and Memorial Sloan Kettering Cancer Center (MSKCC) datasets, demonstrated that increased expression of these two genes predicted for a poorer prognostic outcome in genitourinary cancers. In tumor samples with increased expression of EZH2 and TOP2A, as compared to the tumor samples that did not concurrently overexpress both EZH2 and TOP2A, patients displayed worse overall Regression Free Survival (RFS), which were associated with increase hazard ratio, and tumor staging and grades. . As these poor prognostic markers were consistent across multiple cancer subtypes, we are beginning to explore those genes that are differentially expressed in individuals with concurrent high TOP2A and EZH2 as a means of further characterizing this novel phenotype. Since these two genes are targetable by drugs such as etoposide (a TOP2 poison) and DZNep (an EZH2 inhibitor), it makes them attractive candidates for treatment in those individuals who not only have tumors that highly express these two genes, but also those individuals that have exacerbated existing treatment options. Citation Format: Spencer Rosario, Zafardjan Dalimov, Jason Kirk, Kayla Morrell, Kevin Eng, Leigh Ellis. Increased expression of EZH2 and TOP2A predicts for a poorer prognostic outcome in Genitourinary Cancers. [abstract]. In: Proceedings of the AACR Special Conference on Chromatin and Epigenetics in Cancer; Sep 24-27, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2016;76(2 Suppl):Abstract nr B10.
Read full abstract